Guggenheim raised the firm’s price target on Amgen (AMGN) to $351 from $347 and keeps a Neutral rating on the shares. The firm is updating its company model ahead of Q1 results expected after market close on April 30.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMGN:
- Amgen: Long-Term AI Potential but Limited Near-Term Upside Supports Hold Rating
- Amgen price target raised to $325 from $319 at Truist
- Viridian Therapeutics price target lowered to $36 from $40 at Truist
- Viridian Therapeutics price target lowered to $31 from $37 at Wedbush
- Amgen put volume heavy and directionally bearish